Trial Profile
Randomized phase III study of TS-1 alone versus TS-1 plus CDDP in advanced gastric cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPIRITS
- Sponsors Taiho Pharmaceutical
- 21 Jan 2017 Results (n=1248) of a combined analysis from SPIRITS, TOP-002 and START trials, presented at the 2017 Gastrointestinal Cancers Symposium
- 01 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 01 Mar 2008 Results published in Lancet Oncology.